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Arthritis (RA) group with a clinical classification category of CCC 202. They were
matched with an equal number of respondents without RA as controls in order to
minimize the sample selection bias, using Greedy Match Propensity Score Match-
ing. Pre-disposing, enabling and need variables were matched using Chi-square
tests for categorical variables and t-tests for continuous variables in SAS, version 9.
Health-related quality of life instruments usedwere the Physical Component Sum-
mary (PCS-12) and the Mental Component Summary (MCS-12) of the SF-12 Health
Survey and the EuroQol 5D index. T-tests in STATA (R) were used to measures
group differences. RESULTS: Patients were statiscally matched on nine of ten vari-
ables. Themean (SE) PCS-12 scores for the RA and Non-RA groups were 34.25 (1.03)
and 45.46 (1.07). The mean (SE) MCS-12 scores for the RA and Non-RA groups were
47.50 (1.01) and 51.14 (0.83). The mean (SE) EQ-5D index scores for the RA and
Non-RA groups were 0.74 (0.02) and 0.86 (0.01). All lower scores were significant at
an a priori alpha value of 0.05. CONCLUSIONS: Lower scores on all measures indi-
cate that non- institutionalized adultswith self-reported RheumatoidArthritis (RA)
have a significantly lower health-realated quality of life.
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Fibromyalgia syndrome (FMS) is amulti-symptomdisorder primarily characterizedby
pain. In addition to pain, other symptoms include fatigue, irritable bowel disorder,
psychological disturbances like anxiety, depression, cognitive dysfunction etc. The
ambiguity of the symptoms and their overlapping naturewith other rheumatic disor-
ders poses a huge problem in diagnosis. Meanwhile, patient’s quality of life (QoL) is
compromised and deteriorates further. Hence, a thorough exploration in a clinical
setting is necessary. Generic instruments lack specificity,while the burgeoning symp-
tomspecific instruments present great respondent burden. Validated disease-specific
instruments seem to offer the best medium for complete evaluation of FMS patients.
OBJECTIVES: To identify available validated disease-specific instruments to enable
a comprehensive evaluation of fibromyalgia patients in a clinical setting.The ojec-
tive of this review is to provide clinicians and researchers with summarized infor-
mation on the available instruments and aid them in diagnosis of this disorder.
METHODS: A comprehensive literature review from January 1990 to June 2011 was
conducted with the combination of following key words fibromyalgia, disease-
specific, questionnaires, instruments etc. 58 articles that dealt with disease-spe-
cific instruments in FMS were identified of which 9 articles were included in the
final review. RESULTS: Only nine disease-specific instruments were identified in
literature which can be classified as: a) Diagnostic tools (2 instruments); b) QoL
evaluation tools (6 instruments); and c) Disease knowledge assessment tools (1
instrument). Most instruments possess strong psychometric properties that have
been tested in fibromyalgia patients. This review describes the instruments with
respect to their psychometric properties, strengths, and limitations.
CONCLUSIONS:These instruments can serve as supplementary aids to researchers
and clinicians for screening, evaluating, and monitoring FMS patients.
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OBJECTIVES:Telemedicine is considered a potentially efficient and effectiveway to
provide physical exercise therapy. To foster uptake of telemedicine exercise ser-
vices and to improve treatment compliance, it is important that services address
patients’ needs and preferences. Therefore, this study examines patients’ prefer-
ences of different telemedicine exercise services using a conjoint experiment.
METHODS: Implemented as part of a larger survey, preferences were estimated
using a choice-based conjoint experiment, spanning six relevant attributes of tele-
medicine exercise services. Attributes were indentified by means of qualitative
interviews and an expert focus group and included a) exercise mode and location;
b) presence of monitoring and feedback technology; c) counseling type; d) counsel-
ing frequency; e) flexibility of exercise hours; and f) willingness to accept as ex-
pressed in terms of a reduction in healthcare insurance premiums. Each patient
was presented with 15 choice tasks, consisting of two exercise service profiles and
an opt-out scenario. A bivariate probit regression analysis was used to estimate
preferences. RESULTS: Hundred and three patients were included in the analysis
after checking for patients’ understanding of the questionnaire using a dominant
option validity check. Themost important attribute levels were individual exercise
at gym, the use of monitoring and feedback technology, 100% face-to-face coun-
seling, counseling every session, flexible exercise hours and 45% health care insur-
ance reduction. Assistive telemedicine was preferred the most, over conventional
treatment and home-based telemedicine. Home-based telemedicinewas preferred
the least and ahealth care insurance reduction of 181 eurowould increase its utility
to the level of conventional treatment. CONCLUSIONS: Results show that patient-
centered telemedicine exercise services should integrate feedback andmonitoring
technology during treatment and emphasize the importance of supplementary
face-to-face counseling sessions. Offering health care insurance reduction could be
a way to further foster uptake of these future telemedicine services.
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OBJECTIVES: Rheumatoid arthritis (RA) is an incapacitating disease with prevalence
estimates ranging from 0.5% to 1% in Brazil, which demands early diagnose and ade-
quate treatment to slow down it’s progression. This study is aimed to assess co-mor-
bidity, quality of life (QoL), work/productivity loss, andmedical resource utilization in
patients diagnosed with RA in Brazil.METHODS: A total of 12,000 individuals’ (age
18) self-reported data were collected from 2011 National Health and Wellness
Survey (NHWS) in Brazil, a cross-sectional representative sample of the adult pop-
ulation. QOL was measured by the physical component score (PCS) and mental
component score (MCS) of the Short Form-12 (SF-12). Loss ofwork/productivitywas
measured by the validatedWork Productivity andActivity Impairment instrument.
Medical resource utilization was measured by health care provider utilization,
emergency room visits and hospitalization in the past 6 months. RESULTS: Of the
12,000 respondents, 65 (0.5%) had been diagnosed with RA, fromwhich 58.0% were
female. 45% of RA diagnosed group reported RA related problems once a month or
less, 27% say their problems occur daily, and 28% experience problems more often
than once per month, but not daily. On average, RA patients have been diagnosed
for 14 years. RA diagnosed group was more likely to suffer from the co-morbidities
of pain (59% vs.23%) and fibromyalgia (11%v s.1%), was more likely to visit an
emergency room in the past 6 months (41% vs.21%), presented lower mean PCS
scores (40% vs. 50%) and had higher percentages of absenteeism (9.2% vs.6.5%),
presenteeism (43.3% vs 14.5%)., work productivity loss (47%vs.18.5%) and activity
impairment (46.9% vs.20.3%) when compared to the group not diagnosed with RA.
All mentioned differences were statistically significant (p0.05). CONCLUSIONS:
Based on results from the Brazil NHWS, patients diagnosed with RA suffer from
impairment in QOL, work/productivity loss and more co-morbidities. Findings in-
dicate there is still an unmet medical need in RA patients in Brazil.
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OBJECTIVES: Poor nutrition, low dietary calcium intake, vitamin D deficiency, in-
sufficient exercise, smoking and alcohol usage aremodifiable risk factors that directly
affect bones and are associated with osteoporosis. In Brazil, there are no solid esti-
mates of the magnitude of the condition, due to being a country with a very hetero-
geneous racial, cultural and economic background. This study is aimed to assess co-
morbidity, quality of life (QOL), work/productivity loss, and medical resource
utilization in women with osteoporosis in Brazil. METHODS: A total of 12,000 indi-
viduals’ (age 18) self-reported data were collected from 2011 National Health and
Wellness Survey (NHWS) in Brazil. QOL was measured by the physical component
score (PCS) andmental component score (MCS) of the Short Form-12 (SF-12). Loss of
work/productivity was measured by the validated Work Productivity and Activity
Impairment instrument. Medical resource utilizationwasmeasured by health care
provider, emergency room visits and hospitalization in the past six months.
RESULTS: Of the 6017 female respondents, 179 (3.0%) were diagnosed with osteopo-
rosis (withorwithoutosteopenia) and156 (1.8%)werediagnosedwithosteopeniaonly.
Average age forwomendiagnosedwith osteoporosis/osteopeniawas 59.6 years. Diag-
nosed osteoporosis/osteopenia group reported more co-morbidities (headache 44%,
pain 36%, insomnia 26%, migraine 23%, depression 22%, arthritis 22%), lower mean
scores of PCS (42.6 vs.47.33) and MCS (45.7 vs. 50.3), more patients visited healthcare
providers (93%vs. 79%), and a higher percentage were using any cost-saving strategy
(55%vs. 37%)over thepast 6months compared tonon-osteoporosis/osteopeniagroup.
Furthermore, osteoporosis/osteopenia group reported 35.8% impairment in daily ac-
tivity compared to 23.0% innon-osteoporosis/osteopenia group.All comparisonswere
statistically significant at p 0.05. CONCLUSIONS: Based on results from the Brazil
NHWS, women diagnosed with osteoporosis/osteopenia suffer from impairment in
QOL,work/productivity loss, greater usage of health care resources andmore co-mor-
bidities. Findings indicate there is still an unmet medical need in osteoporosis/os-
teopenia patients in Brazil.
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OBJECTIVES: To measure the quality of life (QOL) in ankylosing sporidylitis (AS)
patients treated with Infliximab in China. METHODS: Patients’ self-reported data
were collected from a longitudinal survey which was conducted between June 10,
2009 and October 18, 2011 in AS patients at 40 urban hospitals in 23 cities in China.
QOL wasmeasured by Short Form-12 (SF-12) and each follow-up visit up to 8 visits.
RESULTS: Of the 609 survey respondents, 13.0% were treated with Infliximab (ex-
perienced-Infliximab group (EIG)) at baseline and follow ups, while 87.0% were not
treated with Infliximab at baseline but went on Infliximab treatment at the follow
ups (new-Infliximab group (NIG)). These two groups had no significant difference
with respect to age, gender and duration. Comparing with those in the NIG at
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